Machine Learning Guided Discovery of Non-Hemolytic Membrane Disruptive Anticancer Peptides

ChemMedChem. 2022 Sep 5;17(17):e202200291. doi: 10.1002/cmdc.202200291. Epub 2022 Aug 5.

Abstract

Most antimicrobial peptides (AMPs) and anticancer peptides (ACPs) fold into membrane disruptive cationic amphiphilic α-helices, many of which are however also unpredictably hemolytic and toxic. Here we exploited the ability of recurrent neural networks (RNN) to distinguish active from inactive and non-hemolytic from hemolytic AMPs and ACPs to discover new non-hemolytic ACPs. Our discovery pipeline involved: 1) sequence generation using either a generative RNN or a genetic algorithm, 2) RNN classification for activity and hemolysis, 3) selection for sequence novelty, helicity and amphiphilicity, and 4) synthesis and testing. Experimental evaluation of thirty-three peptides resulted in eleven active ACPs, four of which were non-hemolytic, with properties resembling those of the natural ACP lasioglossin III. These experiments show the first example of direct machine learning guided discovery of non-hemolytic ACPs.

Keywords: anticancer peptides; chemical space; genetic algorithm; machine learning; peptide design.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Cell Death
  • Hemolysis
  • Humans
  • Machine Learning

Substances

  • Antineoplastic Agents